ReviewThe Korean journal of helicobacter and upper gastrointestinal research2025
Hemostatic Use of Over-the-Scope Clips in Non-Variceal Upper Gastrointestinal Bleeding: A Narrative Review.
Review in The Korean journal of helicobacter and upper gastrointestinal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The over-the-scope clip (OTSC) system is increasingly used for the endoscopic hemostasis of bleeding non-variceal upper gastrointestinal lesions. OTSCs provide secure, full-thickness tissue compression. The Stop the Bleeding Trial (STING-1) was a German multicenter randomized controlled trial (RCT) that compared OTSC to standard treatment (through-the-scope clips and contact thermal devices) for refractory bleeding ulcers. The rate of further bleeding was significantly reduced with the use of OTSC (19 of 33 patients [57.6%] in the standard therapy group and 5 of 33 patients [15.2%] in the OTSC group). As a first-line endoscopic treatment, OTSCs have been compared with standard treatments in five RCTs, including the STING-2 trial. OTSCs are generally superior in controlling bleeding. Therefore, we recommend the use of OTSCs for lesions with a high risk of further bleeding. These include large ulcers (2 cm in size or larger) located at the duodenal bulb and the lesser curve of the stomach, and ulcers with vessels >2 mm in size. We have also used OTSCs for Dieulafoy's lesions, often with thick submucosal arteries. An ongoing RCT is comparing the use of OTSCs with trans-arterial embolization (TAE) for refractory bleeding. TAE is considered the most definitive, but is associated with a 30% rate of further bleeding. The results of the RCT will help define the management algorithm for such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.